Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial
2024 · The Lancet Neurology · 25 citations
https://doi.org/10.1016/s1474-4422(24)00373-9
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
8
Papers
130
Citations
4
h-index
3
i10-index
Helen Bidner is an academic researcher from Technical University of Munich. The author has contributed to research in topics: HIV/AIDS drug development and treatment & HIV-related health complications and treatments & Parkinson's Disease Mechanisms and Treatments. The author has an h-index of 4, co-authored 7 publications.
https://doi.org/10.1016/s1474-4422(24)00373-9
https://doi.org/10.1186/s12981-021-00384-6
Click to start Chat